News & Updates

COVID-19 vaccination appears to be moderately effective at preventing lingering symptoms following SARS-CoV-2 infection, and this effectiveness may increase with the number of doses administered, according to a meta-analysis.

Treatment with isoniazid and rifapentine (HP) either for 1 month daily (1HP) or 3 months weekly (3HP) results in high rates of treatment success among people with a positive latent tuberculosis infection test and without HIV infection, a study has shown. The 3HP regimen has slightly lower rates of adverse reactions, but neither exhibits superiority to the other.

Exposure to fine particulate matter PM2.5 may elevate the risk for Alzheimer’s disease (AD), mainly through direct pathways instead of mediation by common comorbidities, suggests a study.